866-997-4948(US-Canada Toll Free)

Abraxane (Non Small Cell Lung Cancer) Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Non Small Cell Lung Cancer

No. of Pages : 36 Pages

 

GlobalDatas pharmaceuticals report, Abraxane (Non Small Cell Lung Cancer) - Analysis and Forecasts to 2020 provides abraxane sales forecasts for the US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Non Small Cell Lung Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData\'s team of industry experts.

 

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

 

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Abraxane including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Abraxane including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecasts for 2013-2020 for Abraxane in the US, EU5 and Japan

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Contents

 

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 4
2.1 NSCLC Market 4
2.2 Epidemiology 4
2.3 Etiology 6
2.3.1 Tobacco 6
2.3.2 Radon 6
2.3.3 Asbestos 7
2.3.4 Other Environmental Agents 7
2.4 GlobalData Pipeline Report Guidance 8


3 NSCLC Disease: Market Characterization 9
3.1 NSCLC Disease Market 9
3.2 NSCLC Disease Market Forecasts and CAGR 9
3.3 Drivers for the NSCLC Disease Market 9
3.3.1 High Incidence 10
3.3.2 High Mortality Rate 11
3.3.3 Increased Use of Chemotherapy in Early Stages of NSCLC 11
3.3.4 Emergence of Targeted Drugs and Maintenance Therapy 11
3.3.5 Promising Pipeline Drugs 11


4 Tumor-Node-Metastases (TNM) Classification of NSCLC 12


5 Abraxane 15
5.1 Introduction 15
5.2 Mechanism of Action 15
5.3 Clinical Studies 15
5.4 Approval History of Abraxane 17
5.5 Factors Affecting Sales of Abraxane 17
5.5.1 NSCLC Market 17
5.5.2 Relatively High Efficacy 17
5.5.3 Improved Version of Paclitaxel 17
5.5.4 Increasing Competition from Targeted Therapy 18
5.5.5 Low Safety Profile 18
5.6 Drug Risk Benefit Score 18
5.6.1 Efficacy 18
5.6.2 Safety 19
5.6.3 Compliance 19
5.6.4 Dosing Convenience 19
5.7 Intensity of Competition 19
5.8 Sales forecast 19
5.8.1 Target patient Pool of Abraxane 19
5.8.2 Dosing 21
5.8.3 Market Penetration 21
5.8.4 Annual Cost of Therapy 22
5.8.5 Sales Projections of Abraxane 22


6 NSCLC Market: Appendix 31
6.1 Market Definitions 31
6.2 List of Abberiviations 31
6.3 Research Methodology 32
6.3.1 Coverage 32
6.3.2 Secondary Research 33
6.3.3 Forecasting 33
6.3.4 Number of Patients Approved to take the Drug 33
6.3.5 Net Penetration of Drug 33
6.3.6 Net Annual Dosing 34
6.3.7 Annual Cost of Therapy 35
6.3.8 Primary Research 35
6.3.9 Expert Panels 35
6.4 Contact Us 35
6.5 Disclaimer 35
6.6 Sources 36

List of Table


Table 1: NSCLC, Incidences and Mortality, 2008-2030 5
Table 2: NSCLC, Global, Market Size Forecast ($bn), 20092020 9
Table 3: Regionwise Approval of Abraxane 17
Table 4: Drug Risk Benefit Score 18
Table 5: Abraxane, NSCLC, Global Sales Forecast ($m), 20132020 22
Table 6: Abraxne, NSCLC, The US, Sales Forecast ($m), 20132020 23
Table 7: Abraxne, NSCLC, The UK, Sales Forecast ($m), 20132020 24
Table 8: Abraxne, NSCLC, France, Sales Forecast ($m), 20132020 25
Table 9: Abraxne, NSCLC, Germany, Sales Forecast ($m), 20132020 26
Table 10: Abraxne, NSCLC, Germany, Sales Forecast ($m), 20132020 27
Table 11: Abraxne, NSCLC, Spain, Sales Forecast ($m), 20132020 28
Table 12: Abraxne, NSCLC, Japan, Sales Forecast ($m), 20132020 29

List of Chart


Figure 1: Percentage Distribution of Top 20 Diagnosed Cancers 4
Figure 2: Fatality = [(%Distribution of Incidence) (% Distribution Mortality )] of Top 20 Cancers 5
Figure 3: Percentage Distribution of Different Types of NSCLC according to Incidence, 2008 6
Figure 4: % Share of Risk Factors in Developed Countries 7
Figure 5: Per Capita Cigarette Consumption, The US, 1976-2006 7
Figure 6: NSCLC, Global, Market Size Forecast ($bn), 20092020 9
Figure 7: NSCLC, Global, Incidence (in millions), 2008-2030 10
Figure 8: Oncology, Global, Incidence (in millions), 2008-2030 10
Figure 9: Broad Classification of NSCLC 12
Figure 10: Detailed TNM Classification 13
Figure 11: Classification of NSCLC 14
Figure 12: Drug Model Diagram of Abraxane 20
Figure 13: Drug Dosage Diagram of Abraxane 21
Figure 14: Abraxane, NSCLC, Global Sales Forecast ($m), 20132020 22
Figure 15: Abraxne, NSCLC, The US, Sales Forecast ($m), 20132020 23
Figure 16: Abraxne, NSCLC, The UK, Sales Forecast ($m), 20132020 24
Figure 17: Abraxne, NSCLC, France, Sales Forecast ($m), 20132020 25
Figure 18: Abraxne, NSCLC, Germany, Sales Forecast ($m), 20132020 26
Figure 19: Abraxne, NSCLC, Italy, Sales Forecast ($m), 20132020 27
Figure 20: Abraxne, NSCLC, Spain, Sales Forecast ($m), 20132020 28
Figure 21: Abraxne, NSCLC, Japan, Sales Forecast ($m), 20132020 29
Figure 22: Abraxane, NSCLC, Sales Forecast by Country ($m), 2020 30
Figure 23: GlobalData Methodology 32
Figure 24: Drug Model Diagram 34
Figure 25: Patients Approved for the Drug 34

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *